TipRanks
Advertisement
Advertisement
Madrigal Extends Resmetirom Into Pediatric MASH, Boosting Long-Term Upside for MDGL
PremiumCompany AnnouncementsMadrigal Extends Resmetirom Into Pediatric MASH, Boosting Long-Term Upside for MDGL
2M ago
Madrigal Pharmaceuticals Adds Renowned Leader to Board
Premium
Company Announcements
Madrigal Pharmaceuticals Adds Renowned Leader to Board
2M ago
Walmart downgraded, Palantir upgraded: Wall Street’s top analyst calls
Premium
The Fly
Walmart downgraded, Palantir upgraded: Wall Street’s top analyst calls
2M ago
Neutral Stance Maintained as Madrigal’s Growth Prospects Tempered; Price Target Trimmed from $553 to $543
PremiumRatingsNeutral Stance Maintained as Madrigal’s Growth Prospects Tempered; Price Target Trimmed from $553 to $543
2M ago
MDGL: Rezdiffra’s Strong Q2 Momentum, Robust Cash Position, and Expanding MASH Market Penetration Underpin TD Cowen Buy Rating
Premium
Ratings
MDGL: Rezdiffra’s Strong Q2 Momentum, Robust Cash Position, and Expanding MASH Market Penetration Underpin TD Cowen Buy Rating
2M ago
Madrigal Pharmaceuticals reports Q2 EPS ($1.99), consensus ($2.23)
Premium
The Fly
Madrigal Pharmaceuticals reports Q2 EPS ($1.99), consensus ($2.23)
2M ago
Madrigal Pharmaceuticals price target raised to $739 from $737 at Citizens
PremiumThe FlyMadrigal Pharmaceuticals price target raised to $739 from $737 at Citizens
2M ago
Madrigal Pharmaceuticals announces three new resmetirom patents
Premium
The Fly
Madrigal Pharmaceuticals announces three new resmetirom patents
3M ago
Madrigal Shareholders Approve 2026 Equity Compensation Plans
Premium
Company Announcements
Madrigal Shareholders Approve 2026 Equity Compensation Plans
3M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―